June 26, 2019
Taris Bio brings strong evidence of TAR-200’s anti-tumor activity
TARIS Bio posted on Wednesday positive data from its Phase 1b study of TAR-200 for the treatment of patients with muscle invasive bladder cancer (MIBC), neoadjuvant to radical cystectomy (RC).